Miglustat Accord

Miglustat, the active ingredient in Miglustat Accord, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of Niemann‑Pick disease type C and Gaucher disease type 1, providing substrate reduction therapy for patients with these lysosomal storage disorders.

GNH USA supplies Miglustat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Miglustat is used as substrate reduction therapy for lysosomal storage disorders.

Niemann-Pick disease type C: improves neurological function and helps stabilize disease progression. Gaucher disease type 1: reduces spleen and liver size and improves hematologic parameters. Lysosomal storage disorder management: decreases synthesis of glycosphingolipids to limit substrate accumulation.

Miglustat may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Diarrhea: frequent loose stools, often early in treatment. - Nausea: sensation of queasiness that may lessen over time. - Abdominal pain: cramping or discomfort in the stomach area. - Weight loss: unintended reduction in body weight. - Flatulence: increased intestinal gas. - Taste alteration: metallic or altered taste perception.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Liver enzyme elevation: increased ALT or AST levels. - Peripheral neuropathy: tingling or numbness in extremities. - Seizures: rare occurrence of convulsive episodes.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Monitor gastrointestinal tolerance: adjust diet or supportive care as needed. - Assess body weight regularly: intervene if excessive loss occurs. - Evaluate liver function: perform baseline and periodic liver enzyme tests. - Avoid use in patients with known hypersensitivity to miglustat or excipients. - Pregnancy: risk category unknown; avoid unless benefit outweighs potential risk. - Store at room temperature: keep in the original container, protect from moisture.

Miglustat can affect the absorption or efficacy of certain concomitant medicines.

Major Interactions (Avoid): - Co‑administration with other substrate reduction agents: may increase toxicity. - Use with high‑dose sorbitol-containing products: can exacerbate gastrointestinal side effects.

Moderate Interactions (Monitor Closely): - Concomitant oral antibiotics that rely on intestinal transporters: may alter drug levels. - Antidiabetic agents (e.g., metformin): monitor blood glucose for potential hypoglycemia. - Anticoagulants (e.g., warfarin): observe INR values for possible changes.